Nutex Health Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $875.3M | $479.9M | $247.6M | $219.3M | $331.5M |
| Cost of revenue | — | — | — | — | $14.6M |
| Gross profit | $444.3M | $196.3M | $34.8M | $15.4M | $179.3M |
| Research and development | — | — | — | — | $285,880 |
| Operating expenses | $168.7M | $65.6M | $66.5M | $422.0M | $9.0M |
| Operating income | $275.6M | $130.7M | -$31.8M | -$406.6M | $170.3M |
| Interest expense | $22.2M | $19.9M | $16.3M | $12.5M | $6.2M |
| Pretax income | $244.8M | $109.8M | -$48.5M | -$419.6M | $169.5M |
| Income tax expense | $64.4M | $15.0M | -$5.1M | $13.1M | $965,731 |
| Net income | $70.8M | $52.1M | -$45.8M | -$424.8M | $132.6M |
| Balance Sheet | |||||
| Cash and equivalents | $185.6M | $40.6M | $22.0M | $34.3M | $36.1M |
| Current assets | $538.8M | $292.5M | $90.8M | $98.0M | $154.0M |
| Total assets | $918.5M | $655.3M | $398.2M | $431.8M | $394.7M |
| Current liabilities | $157.9M | $154.2M | $58.3M | $54.9M | $37.7M |
| Total liabilities | $495.1M | $466.8M | $319.1M | $311.4M | $203.1M |
| Total debt | $43.5M | $41.4M | $42.4M | $38.3M | $89.4M |
| Stockholders' equity | $329.4M | $132.4M | $61.5M | $95.9M | $114.7M |
| Cash Flow Statement | |||||
| Cash from operations | $248.1M | $23.2M | $1.3M | $50.6M | $173.4M |
| Depreciation and amortization | $20.5M | $19.0M | $17.6M | $13.1M | $7.7M |
| Stock-based compensation | $107.8M | $129,743 | — | $189,581 | $4.0M |
| Capital expenditure | $2.5M | $2.3M | $9.5M | $14.6M | $36.9M |
| Free cash flow | $245.6M | $20.8M | -$8.2M | $36.0M | $136.5M |
| Share repurchases | $5.0M | $0 | $0 | — | — |
| Impairments | $0 | $3.9M | $29.1M | $398.1M | $0 |
Shares outstanding 6.9M
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.